{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Testing Access to the document"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# The ID of a sample document.\n",
    "DOCUMENT_ID = \"1ed2-5_CgDWg5JZ5vLzz9htuW2Fg3JfWJd-UN0jmOwuo\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Please visit this URL to authorize this application: https://accounts.google.com/o/oauth2/auth?response_type=code&client_id=944564052622-39grtjmehc3c8kk9um4pbjtcnmamaash.apps.googleusercontent.com&redirect_uri=http%3A%2F%2Flocalhost%3A55361%2F&scope=https%3A%2F%2Fwww.googleapis.com%2Fauth%2Fdocuments.readonly&state=PH2Ucds2wK2WvGUV9tfpFwiBVzqr1v&access_type=offline\n",
      "The title of the document is: Copy of Viltolarsen- Duchenne Muscular Dystrophy- Drug Article- Dr\n"
     ]
    }
   ],
   "source": [
    "# Google_Oauth_Credentials\\client_secret_944564052622-39grtjmehc3c8kk9um4pbjtcnmamaash.apps.googleusercontent.com.json\n",
    "import os.path\n",
    "\n",
    "from google.auth.transport.requests import Request\n",
    "from google.oauth2.credentials import Credentials\n",
    "from google_auth_oauthlib.flow import InstalledAppFlow\n",
    "from googleapiclient.discovery import build\n",
    "from googleapiclient.errors import HttpError\n",
    "\n",
    "# If modifying these scopes, delete the file token.json.\n",
    "SCOPES = [\"https://www.googleapis.com/auth/documents.readonly\"]\n",
    "\n",
    "\n",
    "def main():\n",
    "  \"\"\"Shows basic usage of the Docs API.\n",
    "  Prints the title of a sample document.\n",
    "  \"\"\"\n",
    "  creds = None\n",
    "  # The file token.json stores the user's access and refresh tokens, and is\n",
    "  # created automatically when the authorization flow completes for the first\n",
    "  # time.\n",
    "  if os.path.exists(\"Google_Oauth_Credentials/token.json\"):\n",
    "    creds = Credentials.from_authorized_user_file(\"Google_Oauth_Credentials/token.json\", SCOPES)\n",
    "  # If there are no (valid) credentials available, let the user log in.\n",
    "  if not creds or not creds.valid:\n",
    "    if creds and creds.expired and creds.refresh_token:\n",
    "      creds.refresh(Request())\n",
    "    else:\n",
    "      flow = InstalledAppFlow.from_client_secrets_file(\n",
    "          \"./client_secret_944564052622-39grtjmehc3c8kk9um4pbjtcnmamaash.apps.googleusercontent.com.json\", SCOPES\n",
    "      )\n",
    "      creds = flow.run_local_server(port=0)\n",
    "    # Save the credentials for the next run\n",
    "    with open(\"./token.json\", \"w\") as token:\n",
    "      token.write(creds.to_json())\n",
    "\n",
    "  try:\n",
    "    service = build(\"docs\", \"v1\", credentials=creds)\n",
    "\n",
    "    # Retrieve the documents contents from the Docs service.\n",
    "    document = service.documents().get(documentId=DOCUMENT_ID).execute()\n",
    "\n",
    "    print(f\"The title of the document is: {document.get('title')}\")\n",
    "  except HttpError as err:\n",
    "    print(err)\n",
    "\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "  main()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Getting the entire content from the google doc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Viltolarsen- Duchenne Muscular Dystrophy- Drug Article-\n",
      "\n",
      "\n",
      "Abstract:\n",
      "Viltolarsen is recommended for Duchenne muscular dystrophy patients who would respond to exon 53 skipping. Read further to know more.\n",
      "\n",
      "Overview:\n",
      "The most common types of lethal syndromes of X-linked genetic pathology are highlighted by Duchenne muscular dystrophy, which gradually leads to muscular atrophy and concomitant respiratory and cardiac dysfunctions. A morpholino oligomer, phosphorodiamidate morpholino oligomers (PMOs) that is an antisense oligonucleotide, can bring the DMD (Duchenne muscular dystrophy) main transcript’s reading frame back through exon skipping during pre-mRNA (messenger ribonucleic acid) splicing. This works as an exon-skipping therapy, targeting exon 53 of the dystrophin gene with the aim of enabling boys affected by certain mutations to generate the dystrophin protein afresh.\n",
      "\n",
      "However, in eight to ten percent of DMD patients worldwide, it became possible to remove exon 53 of the DMD main transcript. On August 12, 2020, the United States Food and Drug Administration expedited approval of Viltolarsen injection for the treatment of individuals with Duchenne muscular dystrophy (DMD).\n",
      "\n",
      "This review study aimed to collate the data on the mechanism of action, pharmacokinetics, and safety of Viltolarsen that has been acquired from both preclinical and clinical studies.\n",
      "\n",
      "Drug Group:\n",
      "Viltolarsen is an agent in the antisense oligonucleotide class of drugs. \n",
      "\n",
      "Available Doses and Dosage Forms:\n",
      "Subcutaneous injection or intravenous is the usual method through which Viltolarsen is administered to the patients. Though the active pharmaceutical ingredients are the same, the concentrations of the two products may be different; however, the medication is usually offered in a convenient form for the patient or their carer to administer on their behalf.  \n",
      "Injection: Vial, single dose: 250 mg/ per five mL; (50 mg/mL) (milligrams per milliliter).\n",
      "\n",
      "For Patients:\n",
      "\u000bWhat Is Duchenne Muscular Dystrophy and How Effective Is Viltolarsen?\n",
      "The progressive hereditary illness, Duchenne Muscular Dystrophy (DMD), is characterized by the degeneration of cardiac, smooth, and skeletal muscles. It is most common in males and occurs in ‘almost one in 3500 live born males’; it is also among the forms of muscular dystrophy that is most frequently reported. This is because the dystrophin gene on the X chromosome codes for the dystrophin protein but is mutated, and this leads to the condition. They describe this protein as one that helps to attach muscle cells to the cell membrane, which is crucial to maintaining the structural properties of those cells.\n",
      "DMD symptoms manifest between the ages of two and six, most commonly with walking, falling, and stair-climbing difficulties. In other areas, the weakness progresses to distal muscles in locations like the hips, shoulders, and pelvis in the early adolescent years; it leads to loss of ambulation. In addition, respiratory muscles may be paralyzed, and cardiac muscles may be affected by cardiomyopathy (disease of heart muscle). A consequence of these effects might mean early death or general poor health and well being for individuals diagnosed with these diseases.\n",
      "At the moment, there is no cure for DMD, nevertheless, present-day treatments enable DMD sufferers to lead much improved lives. Among these are the physical therapy, the regular use of corticosteroids to slow down the process of muscle wasting, and care for cardiac and pulmonary complications.\n",
      "\n",
      "Effectiveness: From clinical trials, Viltolarsen has shown the possibility of treating patients with exon 53 mutation-associated DMD. In the indicated works, it was proved that Viltolarsen increases the level of dystrophin in the tissues of muscles, which is associated with improved muscle function. Patients who received the Viltolarsen were able to slow the progression of the muscular breakdown as compared to those who took a placebo. The benefits of the therapy remain clear and significant, but additional trials are needed to examine the efficacy and harm of the therapy in the long run.\n",
      "\n",
      "\u000bHow Does Viltolarsen Work?\n",
      "An antisense oligonucleotide, Viltolarsen, is designed for DMD patients who have specific mutations (altered genes). The given approach in order to generate a compact but stable dystrophin protein eliminates exon 53 of the dystrophin gene. This may reduce muscle damage and support muscle operation by preserving muscle cell membranes during contractions. Viltolarsen is administered subcutaneously to slow disease progression and improve the patient’s quality of life.\n",
      "\n",
      "What Is the Dosage of Viltolarsen?\n",
      "The amount of Viltolarsen administered depends on the weight and condition of the patient and the power load. It is given subcutaneously once a week with an initial dose of 80 mg per kg (milligrams per kilogram). Cooperation with healthcare providers is important to monitor therapy outcomes and evaluate dosing in case it is necessary. It remains possible at all times to consult healthcare specialists concerning individual dosage instructions.\n",
      "\n",
      "What Are the Things to Inform the Doctor Before Taking the Drug?\n",
      "Tell your doctor about the following before beginning Viltolarsen:\n",
      "Medical History: In the history of adverse drug reactions, special attention should be paid to any history of allergies, particularly to drugs.\n",
      "Current Medication: Some substances that are found in various over-the-counter drugs, vitamins, and herbal remedies can interrupt Viltolarsen; thus, it is best to avoid any contact.\n",
      "Current Conditions: Any continual illnesses, including illnesses of the kidneys or the liver.\n",
      "Vaccination Status: As some of the vaccines need to be administered during the therapy, recent immunizations or vaccinations planned are also important.\n",
      "Pregnancy: If there is, one may talk about pregnancy or breastfeeding because they may influence the further treatment.\n",
      "\n",
      "How Is Viltolarsen Administered?\n",
      "The initial lab tests in patients treated with Viltolarsen are serum cystatin C, urine protein-to-creatinine ratio, and urine dipstick. \n",
      "Just like any other slimming pills, the dosage suggested is about eighty milligrams per kilogram of body weight per week. \n",
      "They should be intravenous or subcutaneous, and the rate should be administered in one-hour intervals. \n",
      "When 100 mL or less of Viltolarsen solution is needed, the quantity should be drawn up in 0.9 percent sodium chloride injection, USP. \n",
      "\n",
      "What Are the Side Effects of Viltolarsen?\n",
      "The side effects were ranked by their frequency, and the incidence of side effects was found to be around 15 percent in the patients treated with Viltolarsen. It included pyrexia (high body temperature), injection site response, cough, and upper respiratory tract infection.\n",
      "\n",
      "Dietary Considerations:\n",
      "There are no particular food intake restrictions while using Viltolarsen, but maintaining a proper diet plays an important role in health improvement for people with DMD.\n",
      "\n",
      "Missed Dose:\n",
      "If the patient forgets a dosage, he or she should take the Viltolarsen as early as possible. In contrast, it is suggested that the missed dosage should ideally be missed, and the normal dosing schedule should be followed, especially if the next dosage is due. The advice given to the patients is that it is very wrong for one to take double the normal dose in a bid to compensate for the dose they failed to take. In any case, consult your healthcare professional depending on the doses that you have lost.\n",
      "\n",
      "Overdose:\n",
      "Overdose generally requires immediate medical intervention on the part of the patient concerned. Specific signs of toxicity may also not be very well-demarcated, though close observation for any reactions beyond the normal side effects is warranted. In this case, the healthcare providers can give the right management depending on the circumstances.\n",
      "\n",
      "Storage \n",
      "Store Viltolarsen at a temperature between 36 degrees Fahrenheit and 46 degrees Fahrenheit (°F) or two degrees Celsius (2°C) and eight degrees Celsius. Avoid freezing. \n",
      "\n",
      "For Doctors:\n",
      "\n",
      "Indication:\n",
      "An antisense oligonucleotide named Viltolarsen is used to treat DMD in individuals whose mutation of the DMD gene has been confirmed to correspond to the skipped exon 53 of the gene. As stated above, due to the reason that Viltolarsen exposure augments dystrophin biosynthesis in skeletal muscle, the indication has been provided for accelerated approval. There are larger possibilities that the continued approval of this indication might hinge with how a confirmatory trial unveils and affirms its therapeutic efficacy.\n",
      "\u000bDose:\n",
      "Injection: Each vial is 250 mg per five mL (50 mg per mL).\n",
      "Initial Dose: 80 milligrams per kilogram of body weight.\n",
      "The injection, in particular, is usually prescribed for use once a week.\n",
      "However, it is important to adhere to the dosage because changing it impacts the clinical response and tolerability of the utilized drugs.\n",
      "\u000bDosing Considerations:\n",
      "Weight-Based Dosing: As the dose depends on the weight of the patient, it is important to constantly monitor the patient’s weight in order to ensure proper dosing.\n",
      "Injection Technique: To minimize injection site responses, special attention should be taken while giving an injection, and for this, the right technique matters a lot. Education concerning safe injection administration should be provided for patients or their caregivers.\n",
      "Monitoring: Because it is crucial to monitor whether the patient is tolerating therapy well and develops side effects, follow-up visits are mandatory.\n",
      "Liver Function Tests: One should do periodic liver function tests as Viltolarsen might lead to elevation of liver enzymes while looking out for any possible liver-related issues.\n",
      "Adherence to Schedule: They should keep to the active dosage and consult their health provider if they lose a dose or have any concerns concerning the treatment plan.\n",
      "\u000bWhat Are the Pharmacological Aspects of Viltolarsen?\n",
      "Pharmacodynamics: The production of a shorter yet functional dystrophin protein is achieved more easily when Viltolarsen is present. From patients with Duchenne Muscular Dystrophy (DMD), this shorter dystrophin may enhance muscular functionality as well as reduce muscular atrophy to some extent because of its ability to restore part of the sarcolemma structure of the muscle cells. Using a validated western blot method, dystrophin protein level was elevated from baseline in all the studies on patients treated with Viltolarsen 80 mg per kg once weekly for 20 to 24 weeks. The experiments of RT-PCR (Reverse transcription polymerase chain reaction), If staining, and mass spectrometry supported the observation of western blot assay. Immunofluorescence labeling confirmed the expected subcellular distribution of shortened dystrophin to the regions of the sarcolemma in the muscle fibers of persons receiving Viltolarsen. \n",
      "\n",
      "Mechanism: In those patients or animals with polymorphisms that would otherwise cause skipping of exon 53, Viltolarsen is designed to interact with the dystrophin pre-mRNA at exon 53, which results in its exclusion in the processing of mature mRNA.\n",
      "The goal of exon 53 skipping is to allow people with genetic mutations in the region that is prone to exon 53 skipping to produce a dystrophin protein that is internally truncated. \n",
      "\n",
      "Pharmacokinetics: \n",
      "Absorption: Subcutaneous injections of Viltolarsen enable it to get rapidly absorbed into the circulatory system of the human body. Following administration, the bioavailability is frequently elevated and it is thus possible to administer therapeutic concentrations.\n",
      "Distribution: Viltolarsen moves into tissues and lung cells, in particular skeletal muscles, upon administration of the preparation, where it becomes a therapeutic agent. This distribution profile may be affected by the characteristics of the patients.\n",
      "Metabolism: Viltolarsen is mainly cleared by the nuclease enzymes, which degrade the oligonucleotide into fragments. Its removal from the system is made easy by this mechanism.\n",
      "Elimination: Viltolarsen’s metabolites are eliminated in the urine, giving the medication half-lives for a few hours of elimination.\n",
      "\n",
      "Toxicity:\n",
      "Viltolarsen is usually well tolerated; nonetheless, there might be some toxicities:\n",
      "Reactions at the Injection Site: Roaring, tingling, or general burning sensation; redness; expansion in size or some specific pain at the affected area.\n",
      "Effects on the Stomach: Diarrhea and nausea.\n",
      "kidney and Liver Toxicity: They may experience changed liver enzyme levels that require constant observation of the liver and kidney.\n",
      "Allergic Responses: In very few cases, the body may have a severe allergic reaction such as rashing or difficulty breathing.\n",
      "\u000bClinical Studies:\n",
      "It has shown great efficiency of Viltolarsen in increasing dystrophin levels in muscle tissue in exon 53 mutation-induced DMD and improving functional outcomes in patients. Important conclusions consist of:\n",
      "Efficacy: Besides establishing the efficaciousness of Viltolarsen for the improvement of muscular functions with no worsening of strength, trials have put forth that patients stand to benefit from it when compared to those with no treatment plan.\n",
      "Safety Profile: The research shows that the majority of the side effects are mild to moderate and suggest a manageable safety profile.\n",
      "Production of Dystrophin: It was observed that muscle samples had far better dystrophin labeling than controls, as well as better clinical results.\n",
      "There are, however, efforts to establish the effects of these prescribed drugs in the long run.\n",
      "\u000bWhat Are the Contraindications of Viltolarsen?\n",
      "None.\n",
      "\n",
      "Warnings and Precautions:\n",
      "Kidney Toxicity: Could cause renal toxicity from findings of experiments on animals. Renal function should be followed; in DMD patients, creatinine does not appear to adequately reflect renal function.\n",
      "Liver Function Monitoring: Some indications using Viltolarsen can lead to an increase in liver enzymes and, apparently, liver toxicity. Hence, liver enzyme checks have to be regular.\n",
      "Hypersensitivity Reactions: Persons with rash, itching, or breathing difficulties should display signs of an allergic reaction closely. If these occur, it becomes necessary that the patient seeks medical attention at once.\n",
      "\n",
      "What Are the Drug Interactions of Viltolarsen?\n",
      "Anticoagulants: There is probably an upswing in bleeding risks.\n",
      "Other Antisense Oligonucleotides: As they can have compound effects, the combination with other similar medications is discouraged.\n",
      "In order to avoid similar encounters, patients should consult the healthcare physician before starting a new prescription or supplementation program.\n",
      "\n",
      "Specific Considerations:\n",
      "Pregnant: Common structural birth defects impact two to four percent of the population in the United States, whereas about 15 to 20 percent of clinically recognized pregnancies end in miscarriage.\n",
      "Lactation: There are no human or animal data to assess the effect of Viltolarsen on milk production, the amount of Viltolarsen in milk, or the effects of Viltolarsen on a breastfed newborn.\n",
      "Pediatrics: Patients with a confirmed DMD gene mutation who can develop exon 53 skippings are eligible for Viltolarsen as a therapy for their treatment regardless of age. \n",
      "Geriatric: Since DMD is more prevalent in young people, little has been studied in the elderly or senior citizens.\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import os.path\n",
    "\n",
    "from google.auth.transport.requests import Request\n",
    "from google.oauth2.credentials import Credentials\n",
    "from google_auth_oauthlib.flow import InstalledAppFlow\n",
    "from googleapiclient.discovery import build\n",
    "from googleapiclient.errors import HttpError\n",
    "\n",
    "SCOPES = 'https://www.googleapis.com/auth/documents.readonly'\n",
    "DISCOVERY_DOC = 'https://docs.googleapis.com/$discovery/rest?version=v1'\n",
    "\n",
    "\n",
    "def get_credentials():\n",
    "  creds = None\n",
    "  # The file token.json stores the user's access and refresh tokens, and is\n",
    "  # created automatically when the authorization flow completes for the first\n",
    "  # time. If the token is deemed invalid, delete it and run this cell again for it to be created again.\n",
    "  if os.path.exists(\"./token.json\"):\n",
    "    creds = Credentials.from_authorized_user_file(\"./token.json\", SCOPES)\n",
    "  # If there are no (valid) credentials available, let the user log in.\n",
    "  if not creds or not creds.valid:\n",
    "    if creds and creds.expired and creds.refresh_token:\n",
    "      creds.refresh(Request())\n",
    "    else:\n",
    "      flow = InstalledAppFlow.from_client_secrets_file(\n",
    "          \"./client_secret_944564052622-39grtjmehc3c8kk9um4pbjtcnmamaash.apps.googleusercontent.com.json\", SCOPES\n",
    "      )\n",
    "      creds = flow.run_local_server(port=0)\n",
    "    # Save the credentials for the next run\n",
    "    with open(\"./token.json\", \"w\") as token:\n",
    "      token.write(creds.to_json())\n",
    "  return creds\n",
    "\n",
    "\n",
    "def add_current_and_child_tabs(tab, all_tabs):\n",
    "  \"\"\"Adds the provided tab to the list of all tabs, and recurses through and\n",
    "  adds all child tabs.\n",
    "\n",
    "  Args:\n",
    "      tab: a Tab from a Google Doc.\n",
    "      all_tabs: a list of all tabs in the document.\n",
    "  \"\"\"\n",
    "  all_tabs.append(tab)\n",
    "  if (tab.get('childTabs')):\n",
    "    for tab in tab.get('childTabs'):\n",
    "      add_current_and_child_tabs(tab, all_tabs)\n",
    "\n",
    "\n",
    "def get_all_tabs(doc):\n",
    "  \"\"\"Returns a flat list of all tabs in the document in the order they would\n",
    "  appear in the UI (top-down ordering). Includes all child tabs.\n",
    "\n",
    "  Args:\n",
    "      doc: a document.\n",
    "  \"\"\"\n",
    "  all_tabs = []\n",
    "  # Iterate over all tabs and recursively add any child tabs to generate a\n",
    "  # flat list of Tabs.\n",
    "  for tab in doc.get('tabs'):\n",
    "    add_current_and_child_tabs(tab, all_tabs)\n",
    "  return all_tabs\n",
    "\n",
    "\n",
    "def read_paragraph_element(element):\n",
    "  \"\"\"Returns the text in the given ParagraphElement.\n",
    "\n",
    "  Args:\n",
    "      element: a ParagraphElement from a Google Doc.\n",
    "  \"\"\"\n",
    "  text_run = element.get('textRun')\n",
    "  if not text_run:\n",
    "    return ''\n",
    "  return text_run.get('content')\n",
    "\n",
    "\n",
    "def read_structural_elements(elements):\n",
    "  \"\"\"Recurses through a list of << Structural Elements >> to read a document's text\n",
    "  where text may be in nested elements.\n",
    "\n",
    "  Args:\n",
    "      elements: a list of Structural Elements.\n",
    "  \"\"\"\n",
    "  text = ''\n",
    "  for value in elements:\n",
    "    if 'paragraph' in value:\n",
    "      elements = value.get('paragraph').get('elements')\n",
    "      for elem in elements:\n",
    "        text += read_paragraph_element(elem)\n",
    "    elif 'table' in value:\n",
    "      # The text in table cells are in nested Structural Elements and tables may\n",
    "      # be nested.\n",
    "      markdown_table = \"\"\n",
    "      headers = []\n",
    "      separator = []\n",
    "\n",
    "      table = value.get('table')\n",
    "\n",
    "      # Assuming you have already fetched the table rows and cells as per your snippet\n",
    "      for index, row in enumerate(table.get('tableRows')):\n",
    "          cells = row.get('tableCells')\n",
    "          markdown_row = \"|\"\n",
    "          for cell in cells:\n",
    "              # Read the text from each cell; assuming the function `read_structural_elements` returns a string\n",
    "              cell_text = read_structural_elements(cell.get('content')).strip()\n",
    "              markdown_row += f\" {cell_text} |\"\n",
    "              \n",
    "              # Setup headers and separators for the first row\n",
    "              if index == 0:\n",
    "                  headers.append(cell_text)\n",
    "                  separator.append('---')\n",
    "\n",
    "          # Append the row to the markdown table\n",
    "          if index == 0:\n",
    "              # Create the header and separator rows only once, for the first data row\n",
    "              markdown_table += \"|\" + \" | \".join(headers) + \"|\\n\"\n",
    "              markdown_table += \"|\" + \" | \".join(separator) + \"|\\n\"\n",
    "          \n",
    "          markdown_table += markdown_row + \"\\n\"\n",
    "      text += markdown_table\n",
    "\n",
    "      # for row in table.get('tableRows'):\n",
    "      #   cells = row.get('tableCells')\n",
    "      #   for cell in cells:\n",
    "      #     text += read_structural_elements(cell.get('content'))\n",
    "    elif 'tableOfContents' in value:\n",
    "      # The text in the TOC is also in a Structural Element.\n",
    "      toc = value.get('tableOfContents')\n",
    "      text += read_structural_elements(toc.get('content'))\n",
    "  return text\n",
    "\n",
    "\n",
    "def main():\n",
    "  \"\"\"Uses the Docs API to print out the text of a document.\"\"\"\n",
    "  credentials = get_credentials()\n",
    "  docs_service = build(\n",
    "      'docs', 'v1', credentials=credentials\n",
    "  )\n",
    "  # Fetch the document with all of the tabs populated, including any nested\n",
    "  # child tabs.\n",
    "  doc = (\n",
    "      docs_service.documents()\n",
    "      .get(documentId=DOCUMENT_ID, includeTabsContent=True)\n",
    "      .execute()\n",
    "  )\n",
    "  all_tabs = get_all_tabs(doc)\n",
    "\n",
    "  # Print the text from each tab in the document.\n",
    "  for tab in all_tabs:\n",
    "    # Get the DocumentTab from the generic Tab.\n",
    "    document_tab = tab.get('documentTab')\n",
    "    doc_content = document_tab.get('body').get('content')\n",
    "    print(read_structural_elements(doc_content))\n",
    "\n",
    "\n",
    "if __name__ == '__main__':\n",
    "  main()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "JhonSnowLabs",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
